Sanofi (SYN) CEO Paul Hudson Hosts 43rd Annual J.P. Morgan Healthcare (Transcript)Seeking Alpha • 01/14/25
SNY's Subcutaneous Sarclisa Proves Non-Inferior to IV Formulation (Revised)Zacks Investment Research • 01/14/25
Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with SanofiBusiness Wire • 01/13/25
Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myelomaGlobeNewsWire • 01/13/25
Sanofi: Underappreciated Powerhouse Primed For Long-Term Growth (Rating Upgrade)Seeking Alpha • 01/10/25
SNY's Subcutaneous Sarclisa Outperforms IV Formulation in Cancer StudyZacks Investment Research • 01/10/25
Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myelomaGlobeNewsWire • 01/09/25
Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic™ Antisense Platform with SanofiBusiness Wire • 01/07/25
Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccinesGlobeNewsWire • 12/23/24
Strength Seen in Sanofi (SNY): Can Its 6.7% Jump Turn into More Strength?Zacks Investment Research • 12/18/24
Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn'sInvestopedia • 12/17/24
BrightInsight Expands Global Digital Partnership with Sanofi to Build Drug Companion Apps for its Major Specialty TherapiesGlobeNewsWire • 12/17/24
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's diseaseGlobeNewsWire • 12/17/24